In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression ( MADRID Spain 19 march 2007

In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression

MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, at a once-daily dose of 60 mg, significantly reduced non-specific pain and emotional symptoms associated with depression in a new, eight-week, placebo-controlled study of 327 adult patients with at least moderate pain and major depression. The results were presented today at the 15th European Congress of Psychiatry (AEP) in Madrid, Spain.

Duloxetine, a member of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRIs), is approved in more than 70 countries for the treatment of major depression.

“Whereas traditionally, the focus has been on treating only emotional symptoms of depression, we now know that the presence of physical symptoms, specifically pain, can obscure the diagnosis and complicate the management of patients,” said Professor Koen Demyttenaere, Department of Psychiatry at University Hospital Gasthuisberg in Belgium and lead study investigator. “In this study of depressed patients with at least moderate pain, duloxetine helped by significantly reducing both painful and emotional symptoms of depression, and in decreasing the interference of pain with functioning.”

In the study:
Average pain scores, the primary outcome measured, decreased significantly among patients treated with duloxetine by 45 percent (on an 11-point Likert scale from 5.7 at baseline to 3.13 at the final visit in Week 8) compared with a decrease of 29 percent (from 5.7 to 4.06) among those taking placebo (p< 0.001).
Duloxetine significantly reduced core emotional symptoms, as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS), by 56 percent (from an average score of 29.6 at baseline to 12.91 at Week 8), compared with a 39-percent reduction (from 29.6 to 18.29) in patients taking placebo (p<0.0001).
53 percent of duloxetine-treated patients reached remis
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat

Post Your Comments:

( MADRID Spain 19 march 2007 - The ant...)In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression,Health